Medicine and Dentistry
Prostate Cancer
100%
Patient
75%
Castration Resistant Prostate Cancer
47%
Therapeutic Procedure
44%
Inpatient
25%
Androgen
22%
Prostate Specific Antigen
20%
Androgen Receptor
17%
Disease
15%
Abiraterone Acetate
14%
Man
13%
Androgen Deprivation Therapy
12%
Clinical Trial
12%
Hormone Therapy
11%
Metastatic Carcinoma
11%
Overall Survival
11%
Combination Therapy
10%
Consensus
9%
Analysis
9%
Survival
8%
Chemotherapy
8%
Malignant Neoplasm
8%
Prednisone
7%
Neoplasm
7%
Development
7%
Docetaxel
7%
Hormone
6%
Disease Exacerbation
6%
Diagnosis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Castration Resistant Prostate Cancer
73%
Prostate Cancer
58%
Abiraterone Acetate
37%
Androgen
35%
Prednisone
29%
Chemotherapy
24%
Docetaxel
24%
Prostate Specific Antigen
22%
Overall Survival
19%
Androgen Receptor
18%
Abiraterone
15%
Clinical Trial
12%
Diseases
12%
Progression Free Survival
9%
Toxicity
9%
Survival
9%
Deterioration
8%
Neoplasm
7%
Hormone
7%
Malignant Neoplasm
6%
Disease Exacerbation
6%
Ketoconazole
5%
Placebo
5%
Adverse Event
5%
Biochemistry, Genetics and Molecular Biology
Androgen Receptor
15%
Mutation
9%
Prostate-Specific Antigen
8%
Overall Survival
6%
Nested Gene
6%
Prednisone
6%
Development
5%
BRCA2
5%